Dyne Therapeutics Inc
For the period ended May 22, 2024. Filed Apr 5, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
May 22, 2024 · Filed Apr 5, 2024
Contents
Summary Compensation Table
The following table sets forth information regarding compensation awarded to, earned by or paid to each of our named executive officers during the periods indicated.
| Name and Principal Position · Year · Salary · Stock Awards · Option Awards · Non-Equity Incentive Plan Compensation · All Other Compensation · Total | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ($) | ($)(1) | ($)(2) | ($)(3) | ($) | ($) | ||||||||||
| Josh Brumm | 2023 | 643,550 | 3,904,582 | 965,225 | 460,138 | 996 | (5) | 5,974,491 | |||||||
| Former President and Chief Executive Officer(4) | 2022 | 610,000 | 1,709,371 | (6) | 1,661,236 | (7) | 335,500 | 996 | (5) | 4,317,103 | |||||
| Jonathan McNeill | 2023 | 430,468 | (8) | 1,046,199 | 522,287 | 230,880 | 996 | (5) | 2,230,830 | ||||||
| Chief Business Officer | |||||||||||||||
| Susanna High | 2023 | 497,888 | 1,032,436 | 255,220 | 258,902 | 996 | (5) | 2,045,442 | |||||||
| Chief Operating Officer | 2022 | 467,500 | 471,680 | 467,116 | 187,000 | 996 | (5) | 1,594,292 | |||||||
(1)
The amounts reported represent the aggregate grant date fair value of stock awards granted in the applicable fiscal year, calculated in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of stock awards in fiscal year 2023 are set forth in Note 7 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
(2)
The amounts reported represent the aggregate grant date fair value of stock options awarded in the applicable fiscal year, calculated in accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of stock options awarded in fiscal year 2023 are set forth in Note 7 to our audited financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023.
(3)
The amounts reported represent performance-based cash bonuses earned by our named executive officers in the applicable year. See “—Narrative Disclosure to Summary Compensation Table—Annual Bonus” below for a general description of the criteria that our board of directors used to determine the performance-based cash bonuses.
(4)
Mr. Brumm resigned as our president and chief executive officer on March 25, 2024.
(5)
The amounts reported represent $813 in long-term disability insurance premiums and $183 in group term life insurance premiums in excess of statutory limits.
(6)
The amount reported includes $165,691 of incremental fair value related to a restricted stock unit award that was modified in June, 2022 to extend the performance period of the award, calculated in accordance with FASB ASC Topic 718.
(7)
The amount reported includes $158,340 of incremental fair value related to an option award that was modified in June, 2022 to extend the performance period of the award, calculated in accordance with FASB ASC Topic 718.
(8)
In 2023, we paid Dr. McNeill an annualized base salary of $416,936 until July 2023, when his annualized base salary increased to $444,000 in connection with his promotion to Chief Business Officer.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.